Canada markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
179.36-2.61 (-1.43%)
At close: 04:00PM EST
179.36 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close181.97
Open179.62
Bid179.17 x 800
Ask179.43 x 800
Day's Range178.04 - 183.10
52 Week Range156.56 - 280.62
Volume109,028
Avg. Volume212,280
Market Cap19.85B
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 29, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.

  • Business Wire

    BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 28, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.

  • Business Wire

    BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass., November 21, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.